A busy Monday for small-cap newsflow brought a landmark dispute resolution, a fundraising milestone, and a string of clinical and exploration catalysts. Kazera Global (AIM:KZG)'s structured settlement over the long-running Aftan arbitration was the standout, sending shares surging nearly 29%, while Maintel Holdings (AIM:MAI) cleared the final conditions on its £5.5m fundraising and Proteome Sciences (AIM:PRM) jumped 15% on a new chemoproteomics contract win.
Kazera Global seals US$10.5m structured Aftan settlement
Kazera Global (AIM:KZG) executed a definitive settlement agreement with Hebei Xinjian Construction, replacing a prior arbitration award with a structured payment schedule running to December 2029. Under the terms, Kazera retains ownership of the Aftan diamond asset until US$7.125m of the total US$10.5m has been received, providing meaningful security against default. The shares rose 28.84% to 1.224p on the news, reflecting the market's relief at converting a contested legal position into a defined cash recovery path.
Maintel fundraising clears final conditions ahead of admission
Maintel Holdings (AIM:MAI) confirmed that all conditions to its £5.5m fundraising have been satisfied following completion of an accompanying refinancing. The clearance removes the last procedural hurdle before admission of the new shares, and the stock responded by climbing 8.11% to 100.0p.
Proteome Sciences wins chemoproteomics contract ahead of new trial
Proteome Sciences (AIM:PRM) secured a clinical contract on its target engagement platform, with a new trial programme expected to follow later in 2026. The win validates the commercial traction of the company's chemoproteomics offering and drove the shares up 15.3% to 1.741p.
BATM Advanced Communications sells non-core units in $37m deal
BATM Advanced Communications (AIM:BVC) agreed to divest a portfolio of medical, pharmaceutical and distribution subsidiaries for $37m, a transaction that will leave the group focused entirely on secure networking, quantum encryption and cybersecurity. The strategic simplification lifted the shares 4.2% to 14.9p.
Ondine Biomedical expects LANTERN Phase 3 readout within weeks
Ondine Biomedical (AIM:OBI) said the database lock for its LANTERN Phase 3 trial is imminent, with statistical analysis to follow and top-line results expected within one to two weeks of that milestone. The tightly defined timeline gives investors a near-term binary event to watch, and the stock edged up 0.72% to 14.605p.
easyJet rejects three Castlelake takeover approaches
IDEX Biometrics provided context on the easyJet situation, in which the airline rebuffed three successive takeover bids from US investor Castlelake. The prospective acquirer structured its approach to satisfy European Union rules requiring EU-controlled ownership of airlines operating within the bloc, but the board declined all three proposals.
Conroy Gold extends Eastern Zone continuity toward Corcaskea
Conroy Gold and Natural Resources reported step-out drill results at its Clontibret project intersecting nine gold-bearing lodes approximately 150 metres north of previous holes. The results reinforce the interpreted structural link between the Eastern Zone and the Corcaskea target, extending the known mineralised corridor and supporting the case for further resource expansion.
Schroders Capital Global Innovation Trust upsizes tender offer to £23.5m
Schroders Capital Global Innovation Trust (LSE:INOV) increased the size of its tender offer to £23.5m, citing portfolio cash generation as the enabling factor. Completion is scheduled for 29 September, and the shares added 1.61% to 17.528p.
ADM Energy names Vega Oil founder as COO ahead of mid-continent close
ADM Energy appointed Chris Czuppon as chief operating officer of its US subsidiary, ADM Energy USA. Czuppon is the founder of Vega Oil, the business ADM is acquiring through its Vega Upstream transaction, which remains on track to complete by the end of June. The appointment brings direct operational expertise into the subsidiary at the point of deal close.
Solvonis Therapeutics hits PK milestone for esketamine AUD programme
Solvonis Therapeutics (AIM:SVNS) reported that bridging pharmacokinetic data for SVN-002 demonstrated its sublingual-buccal delivery route can match intranasal esketamine exposure, a critical requirement for a US IND submission in its alcohol use disorder programme. The milestone cleared a significant regulatory hurdle and sent the shares up 13.23% to 0.214p.
Genflow chairman to speak on RNA therapeutics at BIO International
Genflow Biosciences (AIM:GENF) announced that its non-executive chairman Gad Berdugo will participate in a panel discussion on RNA therapeutics at the BIO International Convention, one of the biotechnology sector's largest annual gatherings. The profile-raising appearance contributed to a 8.64% gain in the shares to 2.2p.
Wishbone Gold hits shallow gold at Red Setter with mineralisation open at depth
Wishbone Gold Di (AIM:WSBN) released first assay results from reverse circulation drilling at its Red Setter project, with gold returned from as shallow as 45 metres. Notably, the deepest hole ended in mineralisation, leaving the system open at depth and pointing to further drilling potential. The results pushed the shares up 9.68% to 25.5p.
GEO Exploration finds visible gold at Gorge Project in Western Australia
GEO Exploration (AIM:GEO) reported that its first field reconnaissance at the recently acquired Gorge Project returned visible and coarse gold across two prospects, with a copper-rich gossan also identified at a third. The early-stage surface findings at the Western Australian project lifted the shares 7.41% to 0.145p.
Forgent begins maiden drill campaign at Peak Hills Gold-Copper Project
Forgent (AIM:FORG) commenced its maiden drilling programme at the Peak Hills gold-copper project in Western Australia, with initial results expected in early August. Despite the operational progress, the shares fell 11.18% to 0.0151p on the day.
Hamak Gold hits best intercept yet at Akoko North in Ghana
Hamak Gold (AIM:HAMA) reported an intersection of 44 metres at 1.61 g/t gold near surface at the Akoko North prospect in Ghana, its strongest result to date. Drilling is now moving to a second target located 13 kilometres south, broadening the exploration programme across the licence. The shares gained 6.0% to 0.795p.
CelLBxHealth revenues halve but cost base cut by £6.6m in turnaround year
CelLBxHealth (AIM:CLBX) reported full-year revenue of £1.4m, a 52% decline year on year, as the AIM-listed circulating tumour cell technology company restructured its operations. The group cut its operating cost base by more than £6.6m and guided for at least 50% revenue growth in 2026, framing the sharp top-line decline as a deliberate reset rather than structural deterioration. The shares fell 10.29% to 1.57p.
ValiRx terminates University of Dundee drug discovery collaboration
ValiRx (AIM:VAL) ended its evaluation agreement with the University of Dundee's Drug Discovery Unit after the candidate technology failed to meet the criteria required for ValiRx to exercise its option to license it. The termination closes out the collaboration without a licensing outcome, and the shares dipped 3.24% to 0.179p.
Synthomer flags strong H1 as Iran conflict boosts Health and Protection demand
Synthomer (LSE:SYNT) said it expects year-on-year progress in 2026, with second-quarter momentum running ahead of its own expectations. Supply chain disruption triggered by the Iran conflict drove elevated volumes in its Health and Protection segment, providing an unexpected tailwind. Despite the positive trading update, the shares fell 4.36% to 109.6p.
NextEnergy Solar Fund grows income and cuts debt as strategic reset advances
NextEnergy Solar Fund (LSE:NESF) grew total income to £141.3m in the year to 31 March and strengthened its cash position as it continued asset disposals and overhauled its dividend policy. The results confirmed the strategic reset is delivering improved financial metrics, though the shares eased 1.3% to 46.5852p.
Avacta doses first patient in AVA6103 Phase 1 trial
Avacta Group (AIM:AVCT) enrolled its first patient in the FOCUS-01 Phase 1 trial of AVA6103, its second-generation cancer therapy. The milestone was supported by £41.5m raised over the past 18 months, extending the group's cash runway to early 2027. The shares added 1.16% to 73.845p.
Anglo Asian Mining appoints Worley for copper feasibility studies
Anglo Asian Mining (AIM:AAZ) hired Worley Europe to complete feasibility studies at its Xarxar and Garadag copper deposits in Azerbaijan, with results expected between mid-2027 and the first half of 2028. The appointment marks a formal step toward development-stage assessment of the two assets, with the shares broadly flat at 388.75p, down 0.32%.
Pantheon Infrastructure commits $55m to US renewable platform Terra-Gen
Pantheon Infrastructure committed approximately £41m to Terra-Gen, a US renewable energy platform operating 4 GW of solar, wind and battery storage assets with a 16 GW development pipeline. The deployment into a scaled, diversified clean energy operator represents a significant capital allocation for the listed infrastructure fund.
Coinsilium raises £17m and builds 182 Bitcoin treasury in transformational 2025
Coinsilium Group (Aquis) tripled its net assets to £14.6m after a series of placings funded a new Bitcoin treasury strategy that accumulated 182 Bitcoin during 2025. The £17m raised across the year repositioned the Aquis-quoted digital asset investor around a hard-asset accumulation model.
Rift Helium maps 12-month drill path after AIM debut
Rift Helium (AIM:RIFT) set out its deployment plan for the £8.1m raised at its April IPO, with proceeds fully committed to a 3D seismic campaign in 2026 and a first drilling campaign in Tanzania in the first half of 2027. The shares edged up 2.22% to 8.075p.
Mila Resources starts first geophysical survey at Monal gold-copper project
Mila Resources (AIM:MILA) commenced an induced polarisation survey at its Monal gold-copper project in Queensland, targeting porphyry-style mineralisation signatures at the Child's prospect. The survey is designed to generate drill-ready targets, marking the first systematic geophysical work at the project. The shares added 2.13% to 1.2p.
Eco Buildings Group reaches second floor on Albania apartment block
Eco Buildings Group (AIM:ECOB) completed the second-floor structure of the first residential block at its Rolling Hills development in Tirane, Albania, with the third and final floor now under construction. The construction milestone at the industrialised housing project lifted the shares 5.53% to 12.3999p.
Distil converts Ardgowan loan note and secures three-year rent credit
Distil (AIM:DIS) completed the early conversion of its £3m convertible loan note in Ardgowan Distillery, receiving £395,000 in cash and a rent waiver of up to £170,000 on its Blackwoods Brand Home, equivalent to approximately three years of payments. The shares slipped 0.91% to 0.0545p.
Nordex secures 484 MW of new US wind orders across three projects
Nordex won three US wind energy contracts totalling 484 MW, comprising 88 turbines across two of its current product lines. The orders add to the German turbine manufacturer's US order book at a time of continued growth in American wind energy procurement.
Fusion Antibodies receives Canadian patent allowance for antibody library technology
Fusion Antibodies (AIM:FAB) received confirmation from Canada's intellectual property office that the claims in its application covering two antibody families and associated design methods are patentable. The allowance extends the geographic reach of the company's IP protection, though the shares fell 4.0% to 12.0p.
Timor-Leste regulator moves to terminate Sunda Energy's Chuditch gas licence
Sunda Energy received a notice of intention to terminate its Production Sharing Contract covering the Chuditch gas field in Timor-Leste, after the company failed to drill an appraisal well by the required contractual deadline. The notice represents a material threat to Sunda's core asset and the company will need to respond to the regulator's action to preserve its position.
Clean Power Hydrogen pivots to licensing after electrolyser incident
Clean Power Hydrogen (AIM:CPH2) announced a fundamental strategic shift away from manufacturing after a hydrogen-oxygen ignition during final factory acceptance testing of its MFE220 electrolyser. The incident has led the company to abandon its manufacturing ambitions entirely and transition to an intellectual-property licensing model. The shares fell 1.98% to 13.6p.
